Seres Therapeutics (MCRB) Competitors $14.08 +0.11 (+0.79%) Closing price 04:00 PM EasternExtended Trading$13.90 -0.19 (-1.31%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MCRB vs. ATYR, SIGA, TRML, CGEM, MBX, RZLT, KMDA, TERN, RGNX, and SVRAShould you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include aTyr Pharma (ATYR), Siga Technologies (SIGA), Tourmaline Bio (TRML), Cullinan Therapeutics (CGEM), MBX Biosciences (MBX), Rezolute (RZLT), Kamada (KMDA), Terns Pharmaceuticals (TERN), REGENXBIO (RGNX), and Savara (SVRA). These companies are all part of the "pharmaceutical products" industry. Seres Therapeutics vs. Its Competitors aTyr Pharma Siga Technologies Tourmaline Bio Cullinan Therapeutics MBX Biosciences Rezolute Kamada Terns Pharmaceuticals REGENXBIO Savara aTyr Pharma (NASDAQ:ATYR) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations. Do analysts prefer ATYR or MCRB? aTyr Pharma currently has a consensus price target of $20.20, suggesting a potential upside of 248.88%. Seres Therapeutics has a consensus price target of $73.67, suggesting a potential upside of 423.20%. Given Seres Therapeutics' higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than aTyr Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Which has higher valuation and earnings, ATYR or MCRB? Seres Therapeutics has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioaTyr PharmaN/AN/A-$64.02M-$0.81-7.15Seres Therapeutics$126.32M0.97$140K-$4.60-3.06 Does the media refer more to ATYR or MCRB? In the previous week, Seres Therapeutics' average media sentiment score of 1.89 beat aTyr Pharma's score of 1.24 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment aTyr Pharma Positive Seres Therapeutics Very Positive Do institutionals and insiders hold more shares of ATYR or MCRB? 61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 3.7% of aTyr Pharma shares are owned by company insiders. Comparatively, 4.7% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, ATYR or MCRB? aTyr Pharma has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.75, indicating that its stock price is 175% more volatile than the S&P 500. Is ATYR or MCRB more profitable? aTyr Pharma's return on equity of -87.09% beat Seres Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets aTyr PharmaN/A -87.09% -64.77% Seres Therapeutics N/A -41,084.76%-55.87% SummarySeres Therapeutics beats aTyr Pharma on 8 of the 14 factors compared between the two stocks. Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MCRB vs. The Competition Export to ExcelMetricSeres TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$122.92M$2.93B$5.50B$9.38BDividend YieldN/A2.46%4.25%4.06%P/E Ratio-3.0620.3128.1019.86Price / Sales0.97183.28380.1579.14Price / CashN/A42.3835.5357.53Price / Book8.757.838.265.72Net Income$140K-$55.11M$3.24B$257.80M7 Day Performance14.01%2.18%0.50%1.07%1 Month Performance92.35%12.98%7.99%11.31%1 Year Performance-52.43%1.98%28.68%17.01% Seres Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MCRBSeres Therapeutics3.4793 of 5 stars$14.08+0.8%$73.67+423.2%-45.0%$122.92M$126.32M-3.06330Positive NewsATYRaTyr Pharma2.3166 of 5 stars$5.53+4.3%$20.20+265.3%+235.6%$492.17M$230K-6.8353High Trading VolumeSIGASiga Technologies2.0012 of 5 stars$6.86+1.3%N/A-26.9%$490.08M$138.72M10.2440TRMLTourmaline Bio2.0016 of 5 stars$18.96+5.5%$49.33+160.2%+16.0%$486.99MN/A-5.9144News CoveragePositive NewsCGEMCullinan Therapeutics1.7427 of 5 stars$7.87+2.2%$30.00+281.2%-59.8%$464.41MN/A-2.7030MBXMBX Biosciences2.3495 of 5 stars$13.87+6.4%$37.50+170.4%N/A$463.59MN/A0.0036News CoveragePositive NewsAnalyst ForecastRZLTRezolute2.4162 of 5 stars$5.32+1.1%$11.83+122.4%+11.9%$454.97MN/A-4.6340KMDAKamada4.3164 of 5 stars$7.78+0.4%$13.00+67.1%+29.9%$447.39M$167.24M26.83360Positive NewsTERNTerns Pharmaceuticals3.7627 of 5 stars$5.11+4.3%$15.63+205.8%-45.7%$446.31MN/A-4.6940RGNXREGENXBIO4.0392 of 5 stars$8.70+0.2%$31.63+263.5%-37.3%$436.39M$83.33M-2.80370SVRASavara2.1801 of 5 stars$2.51+5.0%$5.60+123.1%-53.4%$433.83MN/A-5.2320 Related Companies and Tools Related Companies ATYR Competitors SIGA Competitors TRML Competitors CGEM Competitors MBX Competitors RZLT Competitors KMDA Competitors TERN Competitors RGNX Competitors SVRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MCRB) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
